Chandra Bhagat Pharma Limited Fundamental Analysis (BSE: CBPL.BO)
Chandra Bhagat Pharma Limited Fundamental Analysis (BSE: CBPL.BO)
Chandra Bhagat Pharma Limited (BSE: CBPL.BO) shows weak financial fundamentals with a PE ratio of 12.41, profit margin of 2.62%, and ROE of 9.59%. The company generates $1.2B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 61.3/100 based on profitability, valuation, growth, and balance sheet metrics. The C+ grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze CBPL.BO's fundamental strength across five key dimensions:
Efficiency Score
WeakCBPL.BO struggles to generate sufficient returns from assets.
Valuation Score
ExcellentCBPL.BO trades at attractive valuation levels.
Growth Score
ModerateCBPL.BO shows steady but slowing expansion.
Financial Health Score
ExcellentCBPL.BO maintains a strong and stable balance sheet.
Profitability Score
WeakCBPL.BO struggles to sustain strong margins.
Key Financial Metrics
Is CBPL.BO Expensive or Cheap?
P/E Ratio
CBPL.BO trades at 12.41 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, CBPL.BO's PEG of 0.05 indicates potential undervaluation.
Price to Book
The market values Chandra Bhagat Pharma Limited at 1.14 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 3.40 times EBITDA. This is generally considered low.
How Well Does CBPL.BO Make Money?
Net Profit Margin
For every $100 in sales, Chandra Bhagat Pharma Limited keeps $2.62 as profit after all expenses.
Operating Margin
Core operations generate 16.94 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $9.59 in profit for every $100 of shareholder equity.
ROA
Chandra Bhagat Pharma Limited generates $3.23 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Chandra Bhagat Pharma Limited generates limited operating cash flow of $91.75M, signaling weaker underlying cash strength.
Free Cash Flow
Chandra Bhagat Pharma Limited produces free cash flow of $82.61M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $10.95 in free cash annually.
FCF Yield
CBPL.BO converts 22.09% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
12.41
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.05
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.14
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.32
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.50
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.50
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.10
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.55
vs 25 benchmark
How CBPL.BO Stacks Against Its Sector Peers
| Metric | CBPL.BO Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 12.41 | 30.97 | Better (Cheaper) |
| ROE | 9.59% | 515.00% | Weak |
| Net Margin | 2.62% | 30197.00% | Weak |
| Debt/Equity | 0.50 | 0.53 | Neutral |
| Current Ratio | 1.50 | 5.71 | Neutral |
| ROA | 3.23% | -16.00% (disorted) | Weak |
CBPL.BO outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Chandra Bhagat Pharma Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation